Advertisement

Activation and Function of Unconventional T Cells

  • Walter Gottlieb Land
Chapter

Abstract

Efferent innate immune responses include the function of unconventional T cells with partial innate properties. While most studies of T lymphocytes have focused on T cells involved in adaptive immune responses by reacting to complexes of peptide and major histocompatibility complex proteins, many other types of T cells do not match this paradigm. As described in this chapter, these cells include CD1-restricted natural killer T cells, MR1-restricted mucosal-associated invariant T cells, and gammadelta T cells. Collectively, these T cells are considered unconventional, in part, because they exert partial innate functions and in part because they can recognize non-classical/non-peptide antigens such as lipids, small-molecule metabolites, and specially modified peptides. Unlike conventional T cells, these unconventional T cells are characterized by semi-invariant, invariant, or even germline-encoded T cell receptors which mediate rapid effector responses. Here, evidence in the perspective of the book is reviewed showing that unconventional T cells are not only activated by recognition of cognate antigens but also—directly or indirectly—by various classes of DAMPs emitted during infectious and sterile injury or exposed by transformed malignant cells. In addition, examples of the various efferent functions of unconventional T cells are briefly addressed pointing to their impressive role in orchestrating and regulating immune responses in infectious and sterile inflammation and tumor surveillance.

References

  1. 1.
    Kabelitz D, Peters C, Wesch D, Oberg H-H. Regulatory functions of γδ T cells. Int Immunopharmacol. 2013;16:382–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1567576913000398 CrossRefGoogle Scholar
  2. 2.
    Liuzzi AR, McLaren JE, Price DA, Eberl M. Early innate responses to pathogens: pattern recognition by unconventional human T-cells. Curr Opin Immunol. 2015;36:31–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0952791515000837 CrossRefGoogle Scholar
  3. 3.
    Hung J-T, Huang J-R, Yu AL. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses. J Biomed Sci. 2017;24:22. Available from: http://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-017-0325-0 CrossRefGoogle Scholar
  4. 4.
    Fay NS, Larson EC, Jameson JM. Chronic inflammation and γδ T cells. Front Immunol. 2016;7:210. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27303404 CrossRefGoogle Scholar
  5. 5.
    Zou C, Zhao P, Xiao Z, Han X, Fu F, Fu L. γδ T cells in cancer immunotherapy. Oncotarget. 2017;8:8900–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27823972 PubMedGoogle Scholar
  6. 6.
    Liuzzi AR, Kift-Morgan A, Lopez-Anton M, Friberg IM, Zhang J, Brook AC, et al. Unconventional human T cells accumulate at the site of infection in response to microbial ligands and induce local tissue remodeling. J Immunol. 2016;197:2195–207. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27527598 CrossRefGoogle Scholar
  7. 7.
    Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol. 2009;9:28–38. Available from: http://www.nature.com/doifinder/10.1038/nri2451 CrossRefGoogle Scholar
  8. 8.
    Grant EP, Degano M, Rosat JP, Stenger S, Modlin RL, Wilson IA, et al. Molecular recognition of lipid antigens by T cell receptors. J Exp Med. 1999;189:195–205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9874576 CrossRefGoogle Scholar
  9. 9.
    Mattner J, Debord KL, Ismail N, Goff RD, Cantu C, Zhou D, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature. 2005;434:525–9. Available from: http://www.nature.com/doifinder/10.1038/nature03408 CrossRefGoogle Scholar
  10. 10.
    Brennan PJ, Tatituri RVV, Brigl M, Kim EY, Tuli A, Sanderson JP, et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat Immunol. 2011;12:1202–11. Available from: http://www.nature.com/doifinder/10.1038/ni.2143CrossRefGoogle Scholar
  11. 11.
    Brigl M, Brenner MB. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens. Semin Immunol. 2010;22:79–86. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1044532309001006 CrossRefGoogle Scholar
  12. 12.
    Kinjo Y, Illarionov P, Vela JL, Pei B, Girardi E, Li X, et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol. 2011;12:966–74. Available from: http://www.nature.com/doifinder/10.1038/ni.2096 CrossRefGoogle Scholar
  13. 13.
    Kuylenstierna C, Björkström NK, Andersson SK, Sahlström P, Bosnjak L, Paquin-Proulx D, et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and costimulation of activation by CD1d. Eur J Immunol. 2011;41:1913–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21590763 CrossRefGoogle Scholar
  14. 14.
    Kohlgruber AC, Donado CA, LaMarche NM, Brenner MB, Brennan PJ. Activation strategies for invariant natural killer T cells. Immunogenetics. 2016;68:649–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27457886 CrossRefGoogle Scholar
  15. 15.
    Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol. 2003;4:1230–7. Available from: http://www.nature.com/doifinder/10.1038/ni1002 CrossRefGoogle Scholar
  16. 16.
    Wang J, Cao X, Zhao J, Zhao H, Wei J, Li Q, et al. Critical roles of conventional dendritic cells in promoting T cell-dependent hepatitis through regulating natural killer T cells. Clin Exp Immunol. 2017;188:127–37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27891589 CrossRefGoogle Scholar
  17. 17.
    Wei J, Xia S, Sun H, Zhang S, Wang J, Zhao H, et al. Critical role of dendritic cell-derived IL-27 in antitumor immunity through regulating the recruitment and activation of NK and NKT cells. J Immunol. 2013;191:500–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23733881 CrossRefGoogle Scholar
  18. 18.
    Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 2015;3:575–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26041808 CrossRefGoogle Scholar
  19. 19.
    Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the “Swiss-Army knife” of the immune system. Curr Opin Immunol. 2008;20:358–68. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0952791508000435 CrossRefGoogle Scholar
  20. 20.
    Godfrey DI, Rossjohn J. New ways to turn on NKT cells. J Exp Med. 2011;208:1121–5. Available from: http://www.jem.org/lookup/doi/10.1084/jem.20110983 CrossRefGoogle Scholar
  21. 21.
    Bassiri H, Das R, Guan P, Barrett DM, Brennan PJ, Banerjee PP, et al. iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo. Cancer Immunol Res. 2014;2:59–69. Available from: http://cancerimmunolres.aacrjournals.org/cgi/doi/10.1158/2326-6066.CIR-13-0104 CrossRefGoogle Scholar
  22. 22.
    Wingender G, Krebs P, Beutler B, Kronenberg M. Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency. J Immunol. 2010;185:2721–9. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1001018 CrossRefGoogle Scholar
  23. 23.
    Crowe NY, Uldrich AP, Kyparissoudis K, Hammond KJL, Hayakawa Y, Sidobre S, et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol. 2003;171:4020–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14530322 CrossRefGoogle Scholar
  24. 24.
    Wilson MT, Johansson C, Olivares-Villagómez D, Singh AK, Stanic AK, Wang C-R, et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci U S A. 2003;100:10913–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12960397 CrossRefGoogle Scholar
  25. 25.
    Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, McKenzie BS, et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A. 2008;105:11287–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18685112 CrossRefGoogle Scholar
  26. 26.
    Juno JA, Keynan Y, Fowke KR. Invariant NKT cells: regulation and function during viral infection. PLoS Pathog. 2012;8:e1002838. Available from: http://dx.plos.org/10.1371/journal.ppat.1002838 CrossRefGoogle Scholar
  27. 27.
    Tessmer MS, Fatima A, Paget C, Trottein F, Brossay L. NKT cell immune responses to viral infection. Expert Opin Ther Targets. 2009;13:153–62. Available from: http://www.tandfonline.com/doi/full/10.1517/14712590802653601 CrossRefGoogle Scholar
  28. 28.
    Inafuku M, Li C, Kanda Y, Kawamura T, Takeda K, Oku H, et al. Beta-glucosylceramide administration (i.p.) activates natural killer T cells in vivo and prevents tumor metastasis in mice. Lipids. 2012;47:581–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22426862 CrossRefGoogle Scholar
  29. 29.
    Barthelemy A, Ivanov S, Hassane M, Fontaine J, Heurtault B, Frisch B, et al. Exogenous activation of invariant natural killer T cells by α-galactosylceramide reduces pneumococcal outgrowth and dissemination postinfluenza. MBio. 2016;7:e01440–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27803187 CrossRefGoogle Scholar
  30. 30.
    Kamaladasa A, Wickramasinghe N, Adikari TN, Gomes L, Shyamali NLA, Salio M, et al. Expansion of highly activated invariant natural killer T cells with altered phenotype in acute dengue infection. Clin Exp Immunol. 2016;185:228–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26874822 CrossRefGoogle Scholar
  31. 31.
    Artiaga BL, Yang G, Hutchinson TE, Loeb JC, Richt JA, Lednicky JA, et al. Rapid control of pandemic H1N1 influenza by targeting NKT-cells. Sci Rep. 2016;6:37999. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27897246 CrossRefGoogle Scholar
  32. 32.
    Yang J-Q, Zhou Y, Singh RR. Effects of invariant NKT cells on parasite infections and hygiene hypothesis. J Immunol Res. 2016;2016:1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27563682 CrossRefGoogle Scholar
  33. 33.
    Tian G, Courtney AN, Jena B, Heczey A, Liu D, Marinova E, et al. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016;126:2341–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27183388 CrossRefGoogle Scholar
  34. 34.
    Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, et al. Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras G12D/+ mice. Immunology. 2017;152(1):36–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28419443 CrossRefGoogle Scholar
  35. 35.
    Gao Y, Williams AP. Role of innate T cells in anti-bacterial immunity. Front Immunol. 2015;6:302. Available from: http://journal.frontiersin.org/Article/10.3389/fimmu.2015.00302/abstract CrossRefGoogle Scholar
  36. 36.
    McEwen-Smith RM, Salio M, Cerundolo V. The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res. 2015;3:425–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25941354 CrossRefGoogle Scholar
  37. 37.
    Vincent MS, Leslie DS, Gumperz JE, Xiong X, Grant EP, Brenner MB. CD1-dependent dendritic cell instruction. Nat Immunol. 2002;3:1163–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12415264 CrossRefGoogle Scholar
  38. 38.
    Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol. 2004;22:817–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15032598 CrossRefGoogle Scholar
  39. 39.
    Keller CW, Freigang S, Lünemann JD. Reciprocal crosstalk between dendritic cells and natural killer T cells: mechanisms and therapeutic potential. Front Immunol. 2017;8:570. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28596767 CrossRefGoogle Scholar
  40. 40.
    Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The burgeoning family of unconventional T cells. Nat Immunol. 2015;16:1114–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26482978 CrossRefGoogle Scholar
  41. 41.
    Dasgupta S, Kumar V. Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset. Immunogenetics. 2016;68:665–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27405300 CrossRefGoogle Scholar
  42. 42.
    Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med. 2004;199:947–57. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15051763 CrossRefGoogle Scholar
  43. 43.
    Marrero I, Ware R, Kumar V. Type II NKT cells in inflammation, autoimmunity, microbial immunity, and cancer. Front Immunol. 2015;6:316. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26136748 CrossRefGoogle Scholar
  44. 44.
    Tard C, Rouxel O, Lehuen A. Regulatory role of natural killer T cells in diabetes. Biomed J. 2015;38:484–95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27013448 CrossRefGoogle Scholar
  45. 45.
    Speir M, Hermans IF, Weinkove R. Engaging natural killer T cells as “Universal helpers” for vaccination. Drugs. 2017;77:1–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28005229 CrossRefGoogle Scholar
  46. 46.
    Szabo PA, Anantha RV, Shaler CR, McCormick JK, Haeryfar SMM. CD1d- and MR1-restricted T cells in sepsis. Front Immunol. 2015;6:401. Available from: http://journal.frontiersin.org/Article/10.3389/fimmu.2015.00401/abstract PubMedPubMedCentralGoogle Scholar
  47. 47.
    Moreira ML, Tsuji M, Corbett AJ, Araújo MSS, Teixeira-Carvalho A, Martins-Filho OA, et al. MAIT-cells: a tailor-made mate in the ancient battle against infectious diseases? Immunol Lett. 2017;187:53–60. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0165247817300640 CrossRefGoogle Scholar
  48. 48.
    Keller AN, Corbett AJ, Wubben JM, McCluskey J, Rossjohn J. MAIT cells and MR1-antigen recognition. Curr Opin Immunol. 2017;46:66–74. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0952791517300250 CrossRefGoogle Scholar
  49. 49.
    Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. 2012;491:717–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23051753 CrossRefGoogle Scholar
  50. 50.
    Kawachi I, Maldonado J, Strader C, Gilfillan S. MR1-restricted V alpha 19i mucosal-associated invariant T cells are innate T cells in the gut lamina propria that provide a rapid and diverse cytokine response. J Immunol. 2006;176:1618–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16424191 CrossRefGoogle Scholar
  51. 51.
    Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C, et al. Stepwise development of MAIT cells in mouse and human. PLoS Biol. 2009;7:e54. Available from: http://dx.plos.org/10.1371/journal.pbio.1000054 CrossRefGoogle Scholar
  52. 52.
    Le Bourhis L, Martin E, Péguillet I, Guihot A, Froux N, Coré M, et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat Immunol. 2010;11:701–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20581831 CrossRefGoogle Scholar
  53. 53.
    Dusseaux M, Martin E, Serriari N, Péguillet I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood. 2011;117:1250–9. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2010-08-303,339 CrossRefGoogle Scholar
  54. 54.
    Brozova J, Karlova I, Novak J. Analysis of the phenotype and function of the subpopulations of mucosal-associated invariant T cells. Scand J Immunol. 2016;84:245–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27474379 CrossRefGoogle Scholar
  55. 55.
    Tang X-Z, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol. 2013;190:3142–52. Available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1203218 CrossRefGoogle Scholar
  56. 56.
    Chen Z, Wang H, D’Souza C, Sun S, Kostenko L, Eckle SBG, et al. Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals. Mucosal Immunol. 2017;10:58–68. Available from: http://www.nature.com/doifinder/10.1038/mi.2016.39 CrossRefGoogle Scholar
  57. 57.
    Chiba A, Tajima R, Tomi C, Miyazaki Y, Yamamura T, Miyake S. Mucosal-associated invariant T cells promote inflammation and exacerbate disease in murine models of arthritis. Arthritis Rheum. 2012;64:153–61. Available from: http://doi.wiley.com/10.1002/art.33314 CrossRefGoogle Scholar
  58. 58.
    Ussher JE, Bilton M, Attwod E, Shadwell J, Richardson R, de Lara C, et al. CD161++ CD8+ T cells, including the MAIT cell subset, are specifically activated by IL-12 + IL-18 in a TCR-independent manner. Eur J Immunol. 2014;44:195–203. Available from: http://doi.wiley.com/10.1002/eji.201343509 CrossRefGoogle Scholar
  59. 59.
    Willing A, Leach OA, Ufer F, Attfield KE, Steinbach K, Kursawe N, et al. CD8+ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis. Eur J Immunol. 2014;44:3119–28. Available from: http://doi.wiley.com/10.1002/eji.201344160 CrossRefGoogle Scholar
  60. 60.
    van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, et al. MAIT cells are activated during human viral infections. Nat Commun. 2016;7:11653. Available from: http://www.nature.com/doifinder/10.1038/ncomms11653 CrossRefGoogle Scholar
  61. 61.
    Georgel P, Radosavljevic M, Macquin C, Bahram S. The non-conventional MHC class I MR1 molecule controls infection by Klebsiella pneumoniae in mice. Mol Immunol. 2011;48:769–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21190736 CrossRefGoogle Scholar
  62. 62.
    Kurioka A, Ussher JE, Cosgrove C, Clough C, Fergusson JR, Smith K, et al. MAIT cells are licensed through granzyme exchange to kill bacterially sensitized targets. Mucosal Immunol. 2015;8:429–40. Available from: http://www.nature.com/doifinder/10.1038/mi.2014.81 CrossRefGoogle Scholar
  63. 63.
    Le Bourhis L, Guerri L, Dusseaux M, Martin E, Soudais C, Lantz O. Mucosal-associated invariant T cells: unconventional development and function. Trends Immunol. 2011;32:212–8. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1471490611000408 CrossRefGoogle Scholar
  64. 64.
    Turtle CJ, Delrow J, Joslyn RC, Swanson HM, Basom R, Tabellini L, et al. Innate signals overcome acquired TCR signaling pathway regulation and govern the fate of human CD161(hi) CD8α+ semi-invariant T cells. Blood. 2011;118:2752–62. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2011-02-334,698 CrossRefGoogle Scholar
  65. 65.
    Sattler A, Dang-Heine C, Reinke P, Babel N. IL-15 dependent induction of IL-18 secretion as a feedback mechanism controlling human MAIT-cell effector functions. Eur J Immunol. 2015;45:2286–98. Available from: http://doi.wiley.com/10.1002/eji.201445313 CrossRefGoogle Scholar
  66. 66.
    Bianchini E, De Biasi S, Simone AM, Ferraro D, Sola P, Cossarizza A, et al. Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis. Immunol Lett. 2017;183:1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28119072 CrossRefGoogle Scholar
  67. 67.
    Adams EJ, Gu S, Luoma AM. Human gamma delta T cells: evolution and ligand recognition. Cell Immunol. 2015;296:31–40. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0008874915000945 CrossRefGoogle Scholar
  68. 68.
    Chien Y, Meyer C, Bonneville M. γδ T cells: first line of defense and beyond. Annu Rev Immunol. 2014;32:121–55. Available from: http://www.annualreviews.org/doi/10.1146/annurev-immunol-032713-120,216 CrossRefGoogle Scholar
  69. 69.
    Kabelitz D, Déchanet-Merville J. Editorial: “Recent advances in gamma/delta T cell biology: new ligands, new functions, and new translational perspectives”. Front Immunol. 2015;6:371. Available from: http://journal.frontiersin.org/Article/10.3389/fimmu.2015.00371/abstract CrossRefGoogle Scholar
  70. 70.
    Ribeiro ST, Ribot JC, Silva-Santos B. Five layers of receptor signaling in γδ T-cell differentiation and activation. Front Immunol. 2015;6:15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25674089 CrossRefGoogle Scholar
  71. 71.
    Domae E, Hirai Y, Ikeo T, Goda S, Shimizu Y. Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells. Oncotarget. 2017;8(28):45928–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28521284 CrossRefGoogle Scholar
  72. 72.
    Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10:479–89. Available from: http://www.nature.com/doifinder/10.1038/nri2800 CrossRefGoogle Scholar
  73. 73.
    Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol. 2013;13:88–100. Available from: http://www.nature.com/doifinder/10.1038/nri3384 CrossRefGoogle Scholar
  74. 74.
    Papotto PH, Ribot JC, Silva-Santos B. IL-17(+) γδ T cells as kick-starters of inflammation. Nat Immunol. 2017;18:604–11. Available from: http://www.nature.com/doifinder/10.1038/ni.3726 CrossRefGoogle Scholar
  75. 75.
    Lalor SJ, McLoughlin RM. Memory γδ T cells-newly appreciated protagonists in infection and immunity. Trends Immunol. 2016;37:690–702. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1471490616300886 CrossRefGoogle Scholar
  76. 76.
    Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, et al. Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. Blood. 2011;118:129–38. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2011-01-331,298 CrossRefGoogle Scholar
  77. 77.
    Silva-Santos B. γδ cells making IL-17. Blood. 2011;118:3–5. Available from: http://www.bloodjournal.org/cgi/doi/10.1182/blood-2011-05-351,726 CrossRefGoogle Scholar
  78. 78.
    Khairallah C, Déchanet-Merville J, Capone M. γδ T cell-mediated immunity to cytomegalovirus infection. Front Immunol. 2017;8:105. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28232834 CrossRefGoogle Scholar
  79. 79.
    Cimini E, Viola D, Cabeza-Cabrerizo M, Romanelli A, Tumino N, Sacchi A, et al. Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Negl Trop Dis. 2017;11:e0005645. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28558022 CrossRefGoogle Scholar
  80. 80.
    Lança T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Oncoimmunology. 2012;1:717–25. Available from: http://www.tandfonline.com/doi/abs/10.4161/onci.20068 CrossRefGoogle Scholar
  81. 81.
    Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of V gamma 9 V delta 2 T cells by NKG2D. J Immunol. 2005;175:2144–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16081780 CrossRefGoogle Scholar
  82. 82.
    Rei M, Pennington DJ, Silva-Santos B. The emerging protumor role of γδ T lymphocytes: implications for cancer immunotherapy. Cancer Res. 2015;75:798–802. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25660949 CrossRefGoogle Scholar
  83. 83.
    Cheng M, Hu S. Lung-resident γδ T cells and their roles in lung diseases. Immunology. 2017;151(4):375–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28555812 CrossRefGoogle Scholar
  84. 84.
    Hasan MS, Bergmeier LA, Petrushkin H, Fortune F. Gamma delta (γδ) T cells and their involvement in Behçet’s disease. J Immunol Res. 2015;2015:1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26539557 CrossRefGoogle Scholar
  85. 85.
    Van Acker HH, Anguille S, Van Tendeloo VF, Lion E. Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy. Oncoimmunology. 2015;4:e1021538. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26405575 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of StrasbourgMolecular ImmunoRheumatology, Laboratory of Excellence TransplantexStrasbourgFrance

Personalised recommendations